Authors

74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

Expert Commentary on the Product Profile of Amivantamab-vmjw

In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.

57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers

10 Wire Localization vs Radar Reflector Localization: A Comparison

16 Magseed Versus Wire Localisation: A Comparison

Advanced Penile Cancer Presenting With Renal Failure

“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples

Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.

Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.

3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer

15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.

33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

34 12-Year Review of Surgical Outcomes in Implant-Based Reconstructions With Modification and Optimization of Mastectomy Flap Geometry and Soft Tissue Quality: a Retrospective Review of 900 Implant-Based Breast Reconstructions

29 Cost and Utility of Sentinel Lymph Node Biopsy in Patients Undergoing Breast Conservation Surgery for DCIS

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

71 Beyond the Surface: Suspicious Nipple Lesions

Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy

In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

QOL Improvement in Breast Cancer Noted With YES System

QOL improvements were observed among AYA breast cancer survivors after utilizing a mobile health intervention.

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells